Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib treatment-free remission in chronic phase CML with durable MR4.5 (CAMN107I2201)
jRCT2080222102Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Started Jun 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2080222102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222102.